Prelude Capital Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-1,500
Closed -$142K 1852
2019
Q4
$142K Hold
1,500
0.01% 965
2019
Q3
$130K Buy
+1,500
New +$135K 0.01% 869

Other funds holding NVS

Prelude Capital Management's NVS Position: Q2 2020 in Review

Prelude Capital Management sold out of Novartis (NVS) in Q2 2020, closing a stake of 655 shares — an estimated $54K sold.

Prelude Capital Management first reported a position in NVS in Q1 2015 and held it in 12 quarters. The position peaked at $2.71M in Q2 2019. 1,128 funds tracked by Wall St. Rank hold NVS as of Q2 2020.

  • Prelude Capital Management reported no remaining Novartis position as of Q2 2020 after selling out during the quarter.
  • Prelude Capital Management sold 655 Novartis shares in Q2 2020, an estimated $54K.
  • Prelude Capital Management first reported a position in Novartis in Q1 2015 and held it in 12 quarters.
  • Prelude Capital Management's Novartis position peaked at $2.71M in Q2 2019.
  • 1,128 funds tracked by Wall St. Rank held Novartis as of Q2 2020.

Based on Prelude Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.